Please login to the form below

Not currently logged in
Email:
Password:

Biovail gain Parkinson's drug rights

Biovail has entered into a licensing deal with Kyowa Hakko Kirin for the rights in the US and Canada for products containing istradefylline

Biovail, through its subsidiary Biovail Laboratories International, has entered into a licensing deal with Kyowa Hakko Kirin for the commercialisation rights in the US and Canada for products containing istradefylline – a chemical entity with the potential to treat Parkinson's disease.

The licensing agreement includes an upfront payment of $10m with the potential for a further $20m to be paid in milestone payments through approval from the US Food and Drug Administration (FDA). An additional $35m could also be paid should specific sales-based milestones be met.

Further royalty payments of up to 30 per cent will be made to Kyowa Hakko Kirrin on net commercial sales of products containing istradefylline.

"This transaction again highlights our focus on late-stage speciality central nervous system products," said Bill Wells, Biovail's CEO. 

"Istradefylline represents a novel approach for the treatment of Parkinson's disease and provides another building block within our development pipeline, which now has four programmes targeting unmet medical needs in Parkinson's disease," he continued.

Kyowa Hakko Kirin began clinical trials of istradefylline in 1996. In April 2007, the new drug application (NDA) for registration of istradefylline in the US was submitted to the FDA. 

The results of the phase II clinical trial in Japan demonstrated the efficacy of istradefylline compared to placebo and Kyowa Hakko Kirin is currently conducting a phase III clinical trial in Japan.

3rd June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics